LakeShore Biopharma Co., Ltd. (LSBPW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

LakeShore Biopharma Co., Ltd. (LSBPW) Healthcare & Pipeline Overview

LakeShore Biopharma Co., Ltd. is a Beijing-based biopharmaceutical company specializing in vaccines and therapeutic biologics for infectious diseases and cancer. Utilizing its proprietary PIKA immunomodulating technology, the firm develops innovative treatments, including PIKA rabies and COVID-19 vaccines, operating across China, the US, Singapore, UAE, and the Philippines.

What Is the Investment Thesis for LSBPW?

LakeShore Biopharma Co., Ltd. presents a research profile centered on its proprietary PIKA immunomodulating technology platform, which serves as the foundation for its pipeline of vaccines and therapeutic biologics. A key value driver is the potential of its lead candidates, including the PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and the oncology therapeutic PIKA YS-ON-001, to address significant global health challenges. The company's high gross margin of 82.5% suggests strong product-level profitability once commercialized, indicating efficient manufacturing or premium product positioning. Growth catalysts include successful progression of its pipeline through clinical trials, achieving regulatory approvals in its target markets (China, US, Singapore, UAE, Philippines), and subsequent commercialization efforts. The company's international operational presence further supports market access. However, the current negative profit margin of -16.3% highlights the substantial investment required for research and development and operational scale-up, typical for a biotechnology company in its development phase. The beta of 0.57 indicates lower volatility compared to the broader market, which might appeal to certain investor profiles.

Based on FMP financials and quantitative analysis

LSBPW Key Highlights

Gross Margin: 82.5%, indicating strong product-level profitability before operating expenses.

• Profit Margin: -16.3%, reflecting significant ongoing investments in research and development and operational scale-up.
• Employee Count: 758 employees, supporting its comprehensive R&D, manufacturing, and commercialization efforts.
• Geographic Presence: Operations spanning China, the US, Singapore, the UAE, and the Philippines, indicating an international market focus.
• Proprietary Technology: Development of the PIKA immunomodulating technology platform, a core asset for its product pipeline in vaccines and biologics.

Who Are LSBPW's Competitors?

LSBPW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LSBPW's Key Strengths?

Proprietary PIKA immunomodulating technology platform.

• Diverse product pipeline targeting both infectious diseases and cancer.
• International operational presence across five countries.
• High gross margin of 82.5%, indicating strong product-level profitability.
• Integrated capabilities spanning discovery, development, manufacturing, and commercialization.

What Are LSBPW's Weaknesses?

Negative profit margin of -16.3%, reflecting significant ongoing R&D and operational costs.

• Reliance on successful clinical trial outcomes and regulatory approvals for pipeline products.
• Relatively small market capitalization ($0.00B), potentially limiting access to capital.
• Limited public information on specific clinical trial phases or commercialization timelines for all products.

What Could Drive LSBPW Stock Higher?

LSBPW catalyst: Potential clinical trial readouts for PIKA YS-ON-001, which could provide critical data on its efficacy and safety in oncology.

• Regulatory milestones or approvals for the PIKA rabies vaccine in new international markets, expanding its commercial reach.
• Further commercialization expansion of the PIKA recombinant COVID-19 vaccine, potentially securing new supply agreements.
• Continued development and optimization of the proprietary PIKA immunomodulating technology platform, enhancing its versatility.
• Strategic partnerships or collaborations aimed at accelerating pipeline development or market access in key regions.

What Are the Key Risks for LSBPW?

Financial-distress signal — its Altman Z-Score of -2.87 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or significant delays for any of its pipeline products, particularly PIKA YS-ON-001, could impact future revenue streams.
• Intense competition within the biopharmaceutical sector for vaccines and biologics, potentially limiting market share and pricing power.
• The negative profit margin of -16.3% indicates ongoing operational losses and high R&D expenditures, requiring sustained capital investment.
• Regulatory challenges or delays in obtaining market approvals across different jurisdictions, impacting commercialization timelines.
• Intellectual property disputes or challenges to the proprietary PIKA technology, which could undermine its competitive advantage.

What Are the Growth Opportunities for LSBPW?

• **Expansion of PIKA Rabies Vaccine Commercialization:** The global rabies vaccine market continues to present significant opportunities, particularly in endemic regions. LakeShore Biopharma's PIKA rabies vaccine, leveraging its proprietary immunomodulating technology, aims to offer a differentiated product. Successful regulatory approvals and expanded commercialization efforts in key markets, including China, the Philippines, and potentially other high-incidence areas, could substantially contribute to revenue growth. The market for rabies vaccines is driven by both pre-exposure prophylaxis and post-exposure treatment, with a global market size estimated to be in the hundreds of millions of dollars annually, projected to grow steadily over the next five to ten years due to public health initiatives and increased awareness.
• **Commercialization of PIKA Recombinant COVID-19 Vaccine:** Despite the availability of multiple COVID-19 vaccines, there remains an ongoing need for new formulations, booster shots, and vaccines effective against emerging variants. LakeShore Biopharma's PIKA recombinant COVID-19 vaccine, if proven effective and granted widespread regulatory approval, could capture a share of this substantial global market. The long-term demand for COVID-19 vaccines is expected to transition into an annual or biennial booster market, similar to influenza, representing a multi-billion dollar opportunity over the next decade. Successful market entry and adoption in China, the US, and other operational regions would be a significant growth driver.
• **Advancement and Commercialization of PIKA YS-ON-001 in Oncology:** The oncology market is one of the largest and fastest-growing therapeutic areas globally, with immunotherapies playing an increasingly central role. LakeShore Biopharma's PIKA YS-ON-001 represents its entry into this lucrative segment, targeting cancer with its immunomodulating platform. Successful progression through clinical trials, demonstrating efficacy and safety, followed by regulatory approval, would unlock access to a market valued in the hundreds of billions of dollars. The timeline for this opportunity is contingent on the rigorous clinical development process, typically spanning several years from late-stage trials to market entry.
• **Deepening Geographic Market Penetration:** LakeShore Biopharma currently operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. Each of these markets offers unique growth prospects. By strengthening its commercial infrastructure, forging strategic partnerships, and navigating local regulatory landscapes, the company can deepen its penetration in these existing geographies. For instance, expanding market share in the US, a major pharmaceutical market, or increasing vaccine distribution in populous regions like the Philippines, could significantly boost sales volumes and market presence over the medium term (3-7 years).
• **Leveraging PIKA Platform for New Indications:** The proprietary PIKA immunomodulating technology platform is a versatile asset that could be applied to a broader range of infectious diseases or additional cancer types beyond its current pipeline. This represents a long-term growth opportunity (5-10+ years) to expand the company's therapeutic portfolio. By initiating new research programs or engaging in collaborative partnerships, LakeShore Biopharma could identify and develop novel candidates, thereby diversifying its revenue streams and reducing reliance on its current lead products. The ability to demonstrate platform versatility would enhance its strategic value.

What Threats Does LSBPW Face?

• Intense competition from established pharmaceutical and biotechnology companies.
• Potential for clinical trial failures or unexpected adverse events.
• Stringent and evolving regulatory requirements across different jurisdictions.
• Intellectual property challenges and patent expiry risks.
• Market acceptance and reimbursement challenges for new products.

What Are LSBPW's Competitive Advantages?

• Proprietary PIKA immunomodulating technology platform, offering a unique approach to immune modulation.
• Specialized product pipeline including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
• Potential for intellectual property protection (patents) surrounding its technology and drug candidates.
• Established international operational footprint facilitating global market access and clinical development.
• Expertise in both vaccine and therapeutic biologic development, addressing diverse medical needs.

What Does LSBPW Do?

LakeShore Biopharma Co., Ltd., founded in Beijing, China, in 2002, has evolved into a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative vaccines and therapeutic biologics. The company's strategic focus lies in addressing critical unmet medical needs within the infectious diseases and cancer therapeutic areas. Initially operating as YS Biopharma Co., Ltd., the company underwent a significant rebranding in May 2024, adopting its current name, LakeShore Biopharma Co., Ltd., to better reflect its expanding vision and global aspirations. At the core of LakeShore Biopharma's scientific approach is its proprietary PIKA immunomodulating technology platform. This advanced platform is designed to harness and modulate the body's immune responses, offering a novel pathway for developing highly effective and targeted treatments. The company's product pipeline leverages this technology, featuring several key candidates. These include the PIKA rabies vaccine, aimed at providing enhanced protection against the deadly rabies virus; the PIKA recombinant COVID-19 vaccine, developed to address the ongoing global need for effective coronavirus immunization; and PIKA YS-ON-001, a therapeutic biologic targeting cancer, representing the company's foray into oncology. LakeShore Biopharma's operational footprint extends beyond its home base in China, demonstrating a commitment to international market penetration and global health impact. The company maintains active operations and strategic interests in key regions including the United States, Singapore, the United Arab Emirates, and the Philippines. This multi-geographic presence allows LakeShore Biopharma to engage with diverse regulatory environments, clinical research networks, and patient populations, positioning it to potentially bring its innovative therapies to a broader global audience. The company's integrated model, encompassing discovery through commercialization, underscores its ambition to be a comprehensive player in the biopharmaceutical landscape, driving forward solutions for some of the most pressing health challenges worldwide.

What Products and Services Does LSBPW Offer?

• Discover and develop novel vaccines for infectious diseases.
• Discover and develop therapeutic biologics for cancer.
• Utilize a proprietary PIKA immunomodulating technology platform for product development.
• Manufacture their developed biopharmaceutical products.
• Commercialize vaccines and biologics in multiple international markets.
• Develop specific products such as the PIKA rabies vaccine.
• Advance the PIKA recombinant COVID-19 vaccine.
• Progress the oncology therapeutic PIKA YS-ON-001.

How Does LSBPW Make Money?

• Research and Development (R&D) of proprietary biopharmaceutical products leveraging the PIKA immunomodulating technology.
• Manufacturing of vaccines and therapeutic biologics in-house or through contract organizations.
• Commercialization and sales of approved products through direct sales forces or distribution partnerships in various international markets.
• Monetization of intellectual property through product sales after successful clinical development and regulatory approval.

What Industry Does LSBPW Operate In?

LakeShore Biopharma Co., Ltd. operates within the highly dynamic and innovation-driven biotechnology industry, specifically focusing on the development of vaccines and therapeutic biologics for infectious diseases and cancer. This sector is characterized by significant R&D investment, long development cycles, and stringent regulatory pathways. Current market trends indicate a robust demand for novel immunotherapies and advanced vaccine technologies, particularly in response to emerging infectious disease threats and the growing global burden of cancer. LakeShore Biopharma positions itself within this competitive landscape by leveraging its proprietary PIKA immunomodulating technology platform, aiming to differentiate its product candidates from existing treatments. The company's strategy to target both established infectious diseases like rabies and contemporary challenges like COVID-19, alongside oncology, places it in multiple high-growth segments. Success in this industry is heavily reliant on scientific breakthroughs, clinical efficacy, and effective market access strategies, where LakeShore's international footprint could provide an advantage.

Who Are LSBPW's Key Customers?

• Healthcare providers and hospitals for patient treatment.
• Government health agencies and public health programs for vaccine distribution.
• Patients requiring immunization against infectious diseases like rabies and COVID-19.
• Patients seeking advanced therapeutic options for cancer.
• Markets across China, the United States, Singapore, the United Arab Emirates, and the Philippines.

Company Profile

LakeShore Biopharma Co., Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Wang Xu.

LakeShore Biopharma Co., Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.87 places it in the distress zone, a signal of elevated financial risk.

Return on equity for LakeShore Biopharma Co., Ltd. stands at -18.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.3%, showing how much profit it generates from its asset base. A current ratio of 1.02 indicates the company holds enough short-term assets to cover its near-term obligations.

LSBPW Valuation & Market Position

Relative to its peer group, LSBPW's quantitative score of 54/100 is below the peer average of 76/100.

Wall Street analysts project LakeShore Biopharma Co., Ltd. revenue of about $1.45B for fiscal 2026, with EPS near $0.00.

LSBPW Financials

LSBPW Latest News

No recent news available for LSBPW.

LSBPW Analyst Consensus

LSBPW MoonshotScore

Common Questions About LSBPW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources